Mn Services Vermogensbeheer B.V. Sells 300 Shares of ResMed Inc. (NYSE:RMD)

Mn Services Vermogensbeheer B.V. lessened its holdings in ResMed Inc. (NYSE:RMD) by 0.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 69,678 shares of the medical equipment provider’s stock after selling 300 shares during the quarter. Mn Services Vermogensbeheer B.V.’s holdings in ResMed were worth $11,986,000 at the end of the most recent reporting period.

Several other hedge funds have also added to or reduced their stakes in RMD. Louisiana State Employees Retirement System bought a new stake in ResMed in the fourth quarter valued at approximately $1,531,000. MV Capital Management Inc. boosted its stake in shares of ResMed by 39.0% in the 4th quarter. MV Capital Management Inc. now owns 214 shares of the medical equipment provider’s stock valued at $37,000 after purchasing an additional 60 shares during the last quarter. Simplicity Solutions LLC increased its position in shares of ResMed by 20.6% during the fourth quarter. Simplicity Solutions LLC now owns 3,532 shares of the medical equipment provider’s stock worth $608,000 after buying an additional 604 shares during the period. Vaughan David Investments LLC IL acquired a new stake in shares of ResMed during the fourth quarter worth $29,322,000. Finally, Clarius Group LLC acquired a new position in ResMed in the fourth quarter valued at $245,000. 54.98% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, General Counsel Michael J. Rider sold 200 shares of ResMed stock in a transaction on Friday, March 1st. The stock was sold at an average price of $173.25, for a total transaction of $34,650.00. Following the completion of the sale, the general counsel now owns 6,688 shares of the company’s stock, valued at $1,158,696. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other news, Director Peter C. Farrell sold 10,935 shares of the stock in a transaction on Thursday, February 22nd. The shares were sold at an average price of $182.66, for a total value of $1,997,387.10. Following the transaction, the director now owns 157,404 shares of the company’s stock, valued at approximately $28,751,414.64. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, General Counsel Michael J. Rider sold 200 shares of ResMed stock in a transaction on Friday, March 1st. The stock was sold at an average price of $173.25, for a total transaction of $34,650.00. Following the sale, the general counsel now directly owns 6,688 shares of the company’s stock, valued at $1,158,696. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 11,216 shares of company stock valued at $2,046,617. Company insiders own 1.21% of the company’s stock.

ResMed Price Performance

RMD opened at $185.86 on Monday. The firm has a 50-day moving average price of $186.89 and a 200-day moving average price of $169.64. The company has a quick ratio of 1.89, a current ratio of 3.11 and a debt-to-equity ratio of 0.27. ResMed Inc. has a twelve month low of $132.24 and a twelve month high of $243.52. The company has a market capitalization of $27.34 billion, a price-to-earnings ratio of 30.72, a PEG ratio of 2.30 and a beta of 0.67.

ResMed (NYSE:RMD) last issued its quarterly earnings data on Wednesday, January 24th. The medical equipment provider reported $1.88 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.81 by $0.07. The business had revenue of $1.16 billion for the quarter, compared to analysts’ expectations of $1.15 billion. ResMed had a return on equity of 23.86% and a net margin of 19.77%. The firm’s quarterly revenue was up 12.5% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.66 EPS. Equities analysts expect that ResMed Inc. will post 7.45 EPS for the current year.

ResMed Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Thursday, March 14th. Investors of record on Thursday, February 8th were paid a dividend of $0.48 per share. The ex-dividend date of this dividend was Wednesday, February 7th. This represents a $1.92 annualized dividend and a yield of 1.03%. ResMed’s dividend payout ratio is currently 31.74%.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on RMD. Needham & Company LLC increased their price target on ResMed from $215.00 to $224.00 and gave the stock a “buy” rating in a report on Monday, April 1st. Oppenheimer boosted their price objective on ResMed from $185.00 to $205.00 and gave the stock an “outperform” rating in a report on Tuesday, January 30th. Royal Bank of Canada upped their target price on shares of ResMed from $181.00 to $182.00 and gave the stock a “sector perform” rating in a research note on Thursday, January 25th. Mizuho reiterated a “buy” rating and issued a $215.00 price objective on shares of ResMed in a research note on Wednesday, March 27th. Finally, JPMorgan Chase & Co. boosted their target price on ResMed from $160.00 to $195.00 and gave the stock an “overweight” rating in a research note on Tuesday, January 9th. Four equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $199.20.

ResMed Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. It operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes.